ARCHIVES

No Difference in Toxicity Between IMRT and PRT In Medicare Patients

This article is from The Cancer Letter archive.

Vol. 36 No. 1 | January 25, 2013

Download PDF Visit The Full Archive

Related Articles

FDA examining endpoints for approval of cancer therapies, potential departure from survival as the gold standard, Oncology Division Director Richard Pazdur says in interview.

November 7, 2003

Judah Folkman, Angiogenesis Pioneer, Dead at 74.

January 18, 2008

Gleevec For KIT-positive Tumors Shows 92 Percent Overall Survival

July 29, 2011

Wyden Asks Bristol For documentation To Prove That Taxol Price Is Not “Gouging” Taxpayers

January 29, 1993

NCI Bypass Budget Seeks $1 Billion Increase For FY 2011

February 26, 2010

AACR Grant Programs. NIH RFA Available.

June 29, 2001